MDGL - CIK 0001157601
The table below shows MADRIGAL PHARMACEUTICALS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$189.55M | -$455.57M | -$324.23M | -$224.86M | -$183.92M | -$157.56M |
| Capital expenditure | $467.00K | $1.46M | $1.48M | $217.00K | $209.00K | $334.00K |
| Investing cash flow | $32.32M | -$274.39M | -$502.52M | $206.69M | -$5.05M | $159.78M |
| Dividends paid | - | - | - | - | - |
MADRIGAL PHARMACEUTICALS, INC. reported operating cash flow of -$189.55M for fiscal year 2025. That is up 58.4% from -$455.57M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$17.61M (FY 2016) to -$189.55M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $255.98M | $735.06M | $595.12M | $313.45M | $171.24M | $5.09M |